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Block of NMDA receptor channels 
by endogenous neurosteroids: 
implications for the agonist 
induced conformational states of 
the channel vestibule
Vojtech Vyklicky1, Barbora Krausova1, Jiri Cerny1, Ales Balik1, Martin Zapotocky1, 
Marian Novotny2, Katarina Lichnerova1, Tereza Smejkalova1, Martina Kaniakova1, 
Miloslav Korinek1, Milos Petrovic1,5,6, Petr Kacer3, Martin Horak1, Hana Chodounska4 & 
Ladislav Vyklicky1
N-methyl-D-aspartate receptors (NMDARs) mediate synaptic plasticity, and their dysfunction 
is implicated in multiple brain disorders. NMDARs can be allosterically modulated by numerous 
compounds, including endogenous neurosteroid pregnanolone sulfate. Here, we identify the 
molecular basis of the use-dependent and voltage-independent inhibitory effect of neurosteroids on 
NMDAR responses. The site of action is located at the extracellular vestibule of the receptor’s ion 
channel pore and is accessible after receptor activation. Mutations in the extracellular vestibule in the 
SYTANLAAF motif disrupt the inhibitory effect of negatively charged steroids. In contrast, positively 
charged steroids inhibit mutated NMDAR responses in a voltage-dependent manner. These results, in 
combination with molecular modeling, characterize structure details of the open configuration of the 
NMDAR channel. Our results provide a unique opportunity for the development of new therapeutic 
neurosteroid-based ligands to treat diseases associated with dysfunction of the glutamate system.
N-methyl-D-aspartate receptors (NMDARs) are ligand-gated ion channels permeable to calcium that 
play important roles in synaptogenesis, synaptic plasticity, learning, and memory1,2. However, abnormal 
activation of NMDARs is thought to mediate neuronal degeneration3,4.
Among the powerful allosteric modulators of NMDARs are neurosteroids that have been shown to 
induce potentiation, inhibition or mixed effects5. These steroids represent a broad class of endogenous 
compounds whose site of synthesis and action is in the nervous system itself. They play multiple biologi-
cal roles both during embryogenesis and in adults6. Even though it is difficult to interpret their behavioral 
effects based on affinities to specific neurotransmitter receptors, it is plausible to speculate that neuro-
protective activity and improvements of behavioral outcomes after hippocampal and spinal cord lesions 
are related to the direct action of endogenous neurosteroid 20-oxo-5β -pregnan-3α -yl sulfate (pregnano-
lone sulfate; PA-S) and its structural analogs at NMDARs7–10. Surprisingly, even at high neuroprotective 
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concentrations, they lack psychomimetic behavioral effects typical for use- and voltage-dependent 
NMDAR channel inhibitors9,11.
Kinetic, pharmacological and optical experiments showed that the steroid inhibition was not typical 
for a drug-receptor interaction in an aqueous solution compatible with the hypothesis that steroid accu-
mulation in the plasma membrane is the route by which it accesses a binding site on the NMDAR12. 
Interestingly, the action of PA-S has some characteristics similar to the action of voltage-dependent 
NMDAR channel inhibitors. For example, the access of PA-S to its site of action is conditioned by 
the activation of NMDARs by agonists (use-dependent allosteric inhibition). However, in contrast to 
voltage-dependent inhibitors, the action of both the positively and negatively charged steroids at the 
NMDAR is voltage-independent10,12–15.
Here, we have used electrophysiological and molecular biology techniques in combination with molec-
ular modeling to analyze molecular mechanisms of steroid action at NMDARs. Our results suggest that 
neurosteroids bind in the extracellular vestibule of the NMDAR channel to prevent the permeation of 
small mono and divalent ions. In addition, the model of the NMDAR channel opening provides an expla-
nation for the different contributions of GluN1 and GluN2B subunits to the inhibition by the steroid.
Results
Steroid inhibition of NMDARs is use-dependent. To investigate the dependence of PA-S inhibition 
on NMDAR activation, cDNA encoding for the GluN1 and GluN2B subunits were co-transfected into 
HEK293 cells. Figure 1a shows control responses of the transfected cells to a fast application of glutamate 
(1 mM) recorded in the presence of 10 μ M glycine and no added Mg2+. The responses to a co-application 
of 150 μ M PA-S and glutamate made after the onset of the response to glutamate were inhibited with a 
fast onset (τ f = 30 ± 2 ms (Af = 75 ± 3%); τ s = 579 ± 92 ms; n = 6) and recovered from inhibition with a 
slow offset (τ f = 82 ± 14 ms (Af = 45 ± 9%); τ s = 536 ± 79 ms; n = 6). The time constant of the slow rate of 
recovery from inhibition was 902 ± 201 ms (n = 5) for glutamate and steroid co-application for 30 s. The 
onset of the response to glutamate application (10–90%, 15.5 ± 2.9 ms, n = 5) was not significantly differ-
ent from that recorded immediately after 30 s PA-S (150 μ M) pre-application in the absence of glutamate 
(18.4 ± 1.6 ms, n = 5; P = 0.306). These results show the use-dependent action of PA-S at the NMDAR, 
indicating that in the presence of only glycine, PA-S cannot bind; however, after binding both glutamate 
and glycine, the NMDAR reaches conformational state(s) that allow steroid binding.
Similar results were observed for responses induced by glycine (30 μ M) application made in the con-
tinuous presence of glutamate. To avoid activation of NMDARs in the presence of 1 mM glutamate 
and no added glycine by its residual concentration in the extracellular solution (ECS), 7-Cl-kynurenic 
acid (7-CKA; 100 μ M) was used in the control and during PA-S pre-application (Fig.  1b). The onset 
of responses to glycine application made in the continuous presence of glutamate (1 mM) and imme-
diately after 7-CKA pre-application was fit by a single exponential function (τ = 21 ± 1 ms; n = 5) 
(Fig. 1b). Response to glycine made immediately after 5 s 150 μ M PA-S pre-application in the continu-
ous presence of glutamate (1 mM) was fit by a double exponential function τ f = 29 ± 3 ms (Af = 84 ± 5%); 
τ s = 280 ± 72 ms (n = 5) (Fig.  1b). These data indicate that the binding of either glutamate or glycine 
alone is not sufficient to allow a conformational state(s) of the receptor to which PA-S can bind and 
dissociate on a slow time scale.
Use-dependency is a characteristic feature of NMDAR channel blockers; however, the 
voltage-independent action of PA-S10,13 and voltage-dependent action of blockers indicate distinct sites 
of action at the NMDAR. To explore the PA-S interaction with the NMDAR channel, we analyzed the 
current following the termination of glutamate and steroid co-application (after-current) (Fig. 1c). This 
current is typical for voltage-dependent NMDAR inhibitors; however, in a broader sense it can be inter-
preted as a sudden release of an inhibitor from an activated receptor with the channel being either open 
or reaching the open conformation for a short duration of time before its closure16. Relative charge 
transferred during the after-current following 1 mM glutamate and PA-S (10, 30, 50, 100, 150, 300 μ M) 
co-application was fitted by linear regression with a slope of − 0.26 (Fig. 1d). The negative slope of the 
linear regression indicate “trapping” mechanism of action while the use-independent PA-S washout13 
indicates opposing “foot in the door” mechanism (these terms characterize the molecular mode of inter-
action of two classes of voltage-dependent inhibitors with the ion channel16). This apparent contradiction 
may be explained by the fact that voltage-dependent ion channel inhibitors are assumed to block an open 
ion channel however steroids inhibit several conformational states associated with activated receptor 
(agonist activated with the ion channel open or closed13, and perhaps also the desensitized state of the 
receptor17).
Effect of steroids on mutated receptor. We next analyzed the effect of PA-S on receptors phyloge-
netically closely related to the NMDAR. GluR0 is a potassium-selective prokaryotic glutamate receptor18. 
Glutamate-induced responses of this receptor exhibited profound desensitization that precluded a more 
detailed analysis; however, the superposition of the control responses and those made in the presence 
of PA-S indicate that this receptor was inhibited by the neurosteroid (Supplementary Fig. 1a). Similarly, 
glycine-activated GluN1-4a(F484A)/eGFP-GluN3A receptor18,19 was PA-S sensitive (IC50 = 27 ± 3 μ M; 
n = 7), with a potency similar to that assessed for GluN1/GluN2B receptors (Supplementary Fig. 1b). 
GluN1-4a/GluN3A receptors exhibit rapid desensitization that hampers an analysis of PA-S inhibition. 
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GluN1-4a(F484A) mutation reduces receptor desensitization and allows a more accurate analysis. 
Nevertheless, there was no significant difference in the degree of PA-S inhibition between the mutated 
and WT GluN1-4a subunit in combination with GluN3A. To further specify the site of inhibitory neuros-
teroid action at the NMDAR, we used truncated receptors. Truncation of the N- or C-terminal domain 
of the GluN1-1a and GluN2B subunits had no significant effect on the PA-S inhibition of NMDAR 
Figure 1. Neurosteroid-induced inhibition is use-dependent. (a1) Current response of GluN1/GluN2B 
receptors to glutamate (1 mM) (in the presence of 10 μ M glycine) was inhibited by PA-S (150 μ M) with slow 
off kinetics (left). (a2) The onset of the response to glutamate was not affected by 5 s pre-application of PA-S 
in the presence of 10 μ M glycine (middle). (a3) The off responses to PA-S washout following its application 
in the presence of glutamate and glycine (black trace; dotted box in a1) and of glycine only (red trace; dotted 
box in a2) are shown overlaid. (b1) Control response to PA-S made in the presence of glutamate and glycine. 
(b2) Response to glutamate (1 mM) and glycine (30 μ M) made following glutamate (1 mM) and 7-CKA 
(100 μ M) co-application in the absence of added glycine. (b3) Response to glycine and glutamate made 
following PA-S pre-application for 5 s in the presence of glutamate, 7-CKA, and absence of added glycine. 
(b4) The off responses to PA-S washout following its application in the presence of glutamate and glycine 
(black trace; dotted box in b1) and glutamate, 7-CKA, and absence of added glycine (red trace; dotted box in 
b3) are shown overlaid. (c) Superposition of a control response to glutamate (1 mM) (black) and glutamate 
response made in the presence of PA-S (100 μ M) (red). Inset shows the structure of PA-S. (d) Graph of the 
control-normalized charge transfer during the after-current (Qs/Qc) and the extent of the stationary current 
inhibition (1–(IS/IC)). The after-current was recorded after glutamate and PA-S (10, 30, 50, 100, 150, 300 μ M) 
co-application. Data were fitted with linear regression with a slope of – 0.26 (n = 7).
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responses (GluN1/GluN2B: IC50 = 45 ± 1 μ M (n = 20); GluN1Δ N/GluN2BΔ N: IC50 = 41 ± 2 μ M (n = 4) 
P = 0.174 (Supplementary Fig. 1c); GluN1Δ C/GluN2BΔ C: IC50 = 34 ± 3 μ M (n = 4) P = 0.9).
The results of our electrophysiological experiments on the GluN1/GluN2B receptors (Fig. 1) as well 
as on NMDARs with deleted N-terminal and C-terminal domains (Supplementary Fig. 1c) are compat-
ible with a hypothesis that inhibitory steroids act at the transmembrane domain of the NMDAR. The 
following experiments aimed to identify amino acid residues of the NMDAR that are important for 
inhibitory steroid action. We have directed our attention to amino acids at the extracellular portion of 
the transmembrane domain because sulfated steroids do not readily cross the cytoplasmic membrane12 
and have no obvious effect when intracellularly dialyzed15. Further, we have confined our attention to the 
first and the third transmembrane region (M) of the GluN1 and GluN2B subunits, as GluR0 receptors 
(which lack the M418), are equally PA-S sensitive (Supplementary Fig. 1a).
Figure 2a shows that mutations in the membrane regions of the NMDAR affected the sensitivity to 
PA-S. Eight mutations (GluN1: Y647A, T648A, A649T, N650A/L651A, V656A; GluN2B: S645A, T647A, 
A652T) increased the PA-S IC50 values over two-fold relative to the WT receptor value (IC50 = 42 ± 1 μ M 
(n = 20)). The greatest increase in the PA-S IC50 was observed for the mutation GluN1(T648A)/GluN2B, 
which reached 758 ± 27 μ M (n = 8) (Fig. 2b–e). Amino acid residues whose mutation to alanine decreased 
PA-S affinity are located within or near the highly conserved SYTANLAAF motif20 forming the extracel-
lular vestibule of the channel (Fig. 2f). HEK293 cells transfected with seven mutations (GluN1: L655A; 
GluN2B: F554A, W559A, A648T, N649A, L650A, F653A) either did not respond to glutamate applica-
tion (1 mM) or the responses were too small to reliably assess the degree of PA-S inhibition (tested on 
a minimum of 6 cells). Eight mutations (GluN1: F654A; GluN2B: P547A/S548A, F550A, L551A/E552A, 
F637A/F638A, Y646A, M654A, E657A/E658A) decreased the PA-S IC50 values to less than half of the 
WT receptor value, with the mutation GluN2B(Y646A) increasing PA-S affinity to IC50 = 4.3 ± 0.7 μ M 
(n = 10) (Fig. 2b–e). In addition, amino acid residues whose mutation to alanine increased PA-S affinity 
are located at the surface of the membrane regions (in contact with the membrane lipids), and 5 out of 
8 are aromatic amino acids (Fig. 2g).
The extracellular M3 regions of both the GluN1 and GluN2 subunits, within the SYTANLAAF 
motif, are considered to be a part of the external gate21. Because only the positively charged compounds 
can pass through the extracellular channel vestibule and bind inside the NMDAR channel pore in a 
voltage-dependent manner, we used in the next experiments 5β -pregnan-20-on 3α -yl-[(2-trimethylammonio)-e
thanoate] (PA-A), a positively charged steroid with a ring structure identical to that of PA-S (Fig.  3a). 
Like PA-S, PA-A is a use-dependent NMDAR antagonist, showing an after-current following the termina-
tion of glutamate and PA-A co-application (data not shown). We have shown earlier that PA-A-induced 
inhibition is voltage independent from − 60 to + 60 mV12; however, at highly hyperpolarized membrane 
potentials (< − 60 mV), the relative degree of PA-A inhibition increased (Fig. 3a). Fit to the Boltzmann 
equation (see Eq. 2–4) provided δ = 0.15, PA-A Kd(0 mV) = 335 μ M, and g0 = 0.62 (n = 11). The weak 
voltage dependence of the inhibition of the WT NMDAR by a positively charged PA-A indicates that 
the binding site is located near to the outer border of transmembrane electric field. In contrast to the 
WT NMDAR, the effect of PA-A at GluN1(T648A)/GluN2B receptors was strongly voltage dependent ( 
δ = 0.29, Kd(0 mV) = 340 μ M, g0 = 0.83; n = 7) (Fig. 3b). An intermediate voltage dependence was observed 
for GluN1(A649T)/GluN2B receptors (δ = 0.23, Kd(0 mV) = 745 μ M, g0 = 0.93, n = 8) (Fig.  3b) and 
GluN1(V656A)/GluN2B receptors (δ = 0.19, Kd(0 mV) = 193 μ M, g0 = 1.0 n = 8). In agreement with previ-
ous results, our data indicate that the ring of threonines GluN1(T648) and GluN2B(T647) (TTTT-ring) 
forms the narrowest portion of the ion channel22,23. Replacing threonine for a smaller residue of alanine 
makes the diameter of the open conformation of the channel wider so that the molecule of the steroid 
can move through the extracellular vestibule deeper into the channel pore. As expected for negatively 
charged PA-S, its effect was voltage independent for both the WT and GluN1(T648A)/GluN2B receptors 
(Supplementary Figure 2).
Mutations of amino acids in the SYTANLAAF motif of the AMPA receptor channels result in con-
stitutive opening and cause neurodegeneration in the Lurcher mutant mouse24. A similar effect was 
described for mutations in this motif in the NMDAR25–28. An example of spontaneous activity recorded 
from HEK293 cells transfected with GluN1(T648A)/GluN2B receptors is shown in Supplementary 
Figure 3. In the absence of glutamate and glycine, 0.5–2 nA currents sensitive to Mg2+ appeared. These 
currents were only moderately sensitive to D-amino-5-phosphonopentanoic acid (D-AP5; 100 μ M) and 
7-CKA (100 μ M), competitive antagonists at the glutamate and glycine binding sites of the NMDA29,30. 
Relative spontaneous activity (calculated as the ratio of current recorded in the absence of agonists to 
that recorded in the presence of 1 mM glutamate and 10 μ M glycine) ranged from low levels to 87 ± 3% 
(n = 7), which was observed for GluN1(A649T)/GluN2B receptors. The degree of PA-S (200 μ M) inhi-
bition of spontaneous (13.8 ± 0.7%; n = 4) and agonist-evoked currents (13.6 ± 0.9%; n = 4) in HEK293 
cells transfected with GluN1(T648A)/GluN2B receptors was not significantly different (P = 0.913). Of 71 
functional mutations tested, 31 mutations exhibited relative spontaneous activity (RSA; > 6%) (GluN1: 
T550A/L551A, F558A, W563A, V570A/H571A, I631A/L632A, S646A, Y647A, T648A‡, A649T‡, N650A/
L651A, A652T‡, A653T‡, F654A, V656A‡, L657A/D658A‡, I664A/T665A, G666A/I667A; GluN2B: 
S539A/R540A, V545A/S546A, P553A‡, S555A‡, D557A/V558A, I630A/M631A, V632A/S633A, S645A‡, 
T647A‡, M654A, I655A/Q656A, E657A/E658A, Y659A/V660A‡, G665A/L666A; note that ‡ indicates 
the spontaneous activity described earlier)25–28,31. No correlation was found between the PA-S IC50 
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Figure 2. Mutations in the M1 and M3 regions of the GluN1 and GluN2B subunits alter the inhibitory 
potency of PA-S. (a) A representative response is shown for WT and mutated GluN1/GluN2B receptors. 
Responses mediated by GluN1(T648A)/GluN2B receptors were assessed as a difference between the 
current recorded in the presence of 1 mM Mg2+ (condition that abolished the spontaneous currents) and 
that recorded in the presence of 1 mM glutamate and 10 μ M glycine. While the GluN1(T648A)/GluN2B 
receptors were only slightly affected by PA-S (50 μ M) when compared to the WT receptor, the GluN1/
GluN2B(P547A/S548A) receptors were more sensitive to the steroid. Graph of the relative PA-S affinity for 
NMDARs mutated in the M1 regions of GluN1 (b) and GluN2B (c) or mutated in the M3 regions of GluN1 
(d) and GluN2B (e) are shown. Relative PA-S affinity was determined as the ratio of PA-S IC50 (Equation 
1) determined for mutated receptors and the IC50 for the WT receptor (42 μ M; n = 20). † indicates a non-
responding mutation, i.e. a minimum of six GFP-positive cells responding to 1 mM glutamate application 
with currents < 20 pA. (f) Amino acid residues whose mutations altered PA-S inhibition are depicted in a 
homology model of GluN1/GluN2B. For clarity, only the transmembrane region is shown. GluN1 is colored 
in light blue and GluN2B is colored in light red. Dashed line indicates the boundary between hydrophobic 
and hydrophilic regions of lipid as determined by the OPM database63. Residues whose mutation to 
alanine increased the IC50 for PA-S inhibition of GluN1/GluN2B receptor responses more than two–fold 
(to > 84 μ M) are highlighted in green. (g) Residues whose mutation to alanine decreased the IC50 for PA-S 
inhibition by half (to < 21 μ M) are highlighted in green.
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determined for the mutated receptors and the degree of spontaneous activity (Spearman correlation 
P = 0.113; r2 = 0.084) (Supplementary Fig. 3c). This suggests that the decrease of PA-S activity at the 
mutated receptors is not primarily due to the ability of these receptors to spontaneously open.
Access of neurosteroids to the NMDAR. The amphipathic character of the PA-S molecule predicts 
this steroid’s propensity to form aggregates in aqueous solutions. Light scattering analysis of PA-S (5 nM 
Figure 3. Current-to-voltage relation of the steroid action at the WT and mutated NMDARs. (a) 
Representative current of responses of GluN1/GluN2B receptors to glutamate (1 mM) recorded at – 80 and 
+ 40 mV. Glutamate-evoked currents recorded at each of the membrane potentials indicated are reversibly 
inhibited by a co-application of PA-A (20 μ M, indicated by the open bar). Plot of the amplitudes of control 
responses (open symbols) and those induced in the presence of PA-A (20 μ M) (closed symbols) versus 
the holding potential. Control responses were fit by a linear equation and normalized to have a slope of 
1. Responses recorded in the presence of PA-A were normalized with respect to their control and each 
cell fit to the Boltzmann equation (Eq. 2–4). Due to the weak voltage dependence of PA-A, the values of 
δ = 0.15 and PA-A Kd(0 mV) = 335 μ M have to be interpreted cautiously. Data points are mean ± SEM for 6 
cells. (b) GluN1(T648A)/GluN2B receptor responses induced by the washout of 1 mM Mg2+ and 30 μ M 
Zn2+ (the condition blocking the agonist-independent NMDAR activity) and recorded in the presence 
of 1 mM glutamate and 10 μ M glycine. Responses were reversibly inhibited by a co-application of PA-A 
(20 μ M; indicated by the open bar) at a holding potential – 90 mV. PA-A had only a small inhibitory effect 
at a holding potential + 45 mV. Plot of the relative degree of PA-A inhibition versus the holding potential 
is shown for GluN1(T648A)/GluN2B (○) and GluN1(A649T)/GluN2B (Δ ) receptor responses. Control 
responses were fit by a linear equation, responses recorded in the presence of PA-A were normalized 
with respect to the control response and fit to the Boltzmann equation (δ = 0.29, g0 = 0.83, and PA-A 
Kd(0 mV) = 340 μ M for GluN1(T648A)/GluN2B receptor responses (n = 7); δ = 0.23, g0 = 0.93 and PA-A 
Kd(0 mV) = 745 μ M GluN1(A649T)/GluN2B receptor responses (n = 8)). Data points are mean ± SEM.
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to 150 μ M) in ECS confirmed this prediction and indicated a presence of two particle sizes at > 300 nM 
PA-S; since the longitudinal axis of the PA-S vdW surface is 1.56 nm and the steroid molecule is expected 
to be hydrated, we suppose that the small particle size (~2.5 nm) represents a single steroid molecule. 
Larger aggregates represent an agglomeration complex (Supplementary Fig. 4). Light scattering data 
indicate that the critical aggregate concentration (CAC) for PA-S is ~300 nM. By definition, at < CAC the 
monomer concentration of the steroid increases with the steroid added; however, at > CAC aggregates 
form and all additional steroid molecules added to the system go into aggregates32.
Our next experiments aimed to elucidate the mechanism that accounts for the apparent discrepancy 
between the PA-S concentration at which its monomer concentration changes with the added steroid 
(< CAC i.e ≤ 300 nM) and the PA-S dose-response relationship at NMDARs (10 to 300 μ M). The system 
containing monomer and aggregate forms of the solute has the general properties of colloidal solutions; 
however, at sites located near the membrane, one must take into account local increases in the con-
centration of the monomer form of the steroid due to its diffusion from the cell membrane33 (Fig. 4a). 
This scheme assumes that after its association with the membrane, the steroid leaves the membrane 
as a monomer, aggregate and mixed aggregate. We used capacitance measurements to infer the rate 
of steroid association and exit from the membrane (Fig.  4b,c). Fast application of PA-S (150 μ M) onto 
non-transfected HEK293 cells for 1 s resulted in ~3% capacitance increase during the steroid application; 
after the steroid washout, the capacitance returned to its original level with a double exponential time 
course (τ f < 5 ms (likely affected by the rate of the solution exchange around the cell); τ s = 222 ± 8 ms 
(As = 41 ± 2%); n = 7).
At PA-S concentrations relevant to its effect at the NMDAR, the vast majority of the steroid exists in 
rather large (~400 nm) aggregates (Supplementary Fig. 4). Consequently, it was expected that diffusion 
of a large molecular complex to and from the narrow space of the cell and dish contact would be slow 
and likely limit the rate of steroid-induced capacitance change. This assumption was confirmed when 
lifted cells (detached from the culture dish) were used (Fig.  4c). Under these conditions, only the fast 
component of the capacitance change after PA-S washout was resolved, and it remained too fast to be 
assessed accurately (τ < 5 ms; n = 5) (Fig. 4c).
Lifted GluN1/GluN2B transfected HEK293 cells were used to assess the rate of steroid association and 
dissociation from the receptor (Fig. 4d). In contrast to capacitance measurements on lifted cells (where 
only the fast component characterized the onset and offset of 150 μ M PA-S induced capacitance changes), 
the onset of the response induced by 150 μ M PA-S co-application with the glutamate was fitted by a dou-
ble exponential function (τ f = 10.8 ± 2.2 ms; τ s = 480 ± 108 ms (As = 20 ± 4%); n = 5; significantly faster 
than in attached cells). The fast component of the onset of inhibition was significantly (P = 0.010) slower 
than the solution exchange time determined in lifted cells (see Methods) (Fig. 4d). Similarly, the off rate 
was best fitted by a double exponential function (τ f = 14.3 ± 1.7 ms; τ s = 311 ± 70 ms (As = 41 ± 6%); 
n = 5; significantly faster than in attached cells). These data indicate that the slow offset kinetics of PA-S 
inhibition are primarily due to the slow kinetics of steroid unbinding from the receptor and that steroid 
diffusion from narrow spaces (like the cell-dish contact) may further slow the macroscopic rate of steroid 
washout.
The equilibrium concentration of PA-S in the membrane was assessed biochemically using mem-
brane ghosts prepared from rat erythrocytes. The aqueous PA-S concentration was reduced following 
equilibration with membrane ghosts (see Methods). The volume concentration of PA-S was calculated 
from the difference in the concentrations as described in the caption to Supplementary Fig. 5. Assuming 
that PA-S disperses only in the extracellular membrane leaf (see Methods), when [PA-S]total = 55.7 μ M 
(corresponding to the IC50 value) the membrane concentration [PA-S]membrane = 4.32 nM/m2 (i.e., 2600 
molecules/μ m2). The flux Jout of steroid from the membrane into the aqueous phase is given by the 
product of [PA-S]membrane and the rate koff of steroid dissociation from the membrane. As the measured 
fast dissociation time constant τ s was approximately 1 ms or faster, koff ≥ 1000/sec and the flux Jout is at 
least 4.3 μ M s−1 m−2.
At equilibrium, the dissociation of monomers from the membrane (flux Jout) is balanced by two pro-
cesses in the aqueous phase: the diffusion of monomers away from the membrane and aggregation of 
monomers into aggregates. This balance establishes a steady spatial profile of the concentration of PA-S 
monomer, with the highest concentration reached in the immediate vicinity of the membrane and the 
CAC (300 nM) reached far from the membrane. Estimates based on solving a simplified reaction-diffusion 
equation in the unstirred layer (Supplementary Text 1) indicate that the PA-S monomer concentration 
near the membrane exceeds 2 μ M (see Supplementary Fig. 6). Depending on the value of koff and on the 
rate of monomer aggregation, concentrations on the order of 10 μ M may be reached. Lower estimates 
would be obtained if a significant portion of PA-S dissociated from the membrane in the form of aggre-
gates.
Discussion
Responses mediated by GluN1/GluN2B are inhibited by PA-A with signs of weak voltage dependence at 
highly hyperpolarized membrane potentials. In contrast, responses mediated by GluN1(T648A)/GluN2B 
receptors are blocked in a voltage-dependent manner (Fig. 3), indicating that the extracellular vestibule 
opens to a diameter that allows PA-A to move to the central pore cavity and block the ion flow. This 
difference was used to develop a model of the open state of the NMDAR channel and to infer on the 
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steroid-NMDAR interaction. Firstly, we built a homology model of the NMDAR where T648 (GluN1) 
was mutated to alanine, and then 100 models differing in the diagonal distance (displacement up to 
20 Å with 0.2 Å increment; see Methods) between the topmost M3 residues of both GluN1 and GluN2B 
(D658 to D658 (GluN1) and E657 to E657 (GluN2B); the DEDE ring) were obtained. The model with the 
vestibule open wide enough to allow PA-A to move from the extracellular site to the ion channel cavity 
was considered to mimic the open state of the NMDAR (Fig. 5a–e).
Our model almost certainly represents an oversimplification of the reality; it can nevertheless serve 
as a guide for deriving experimentally testable hypotheses. It predicts that even a small movement of 
the M3 helices from the closed to the open state first brings closer the A648 (or T648) residues of the 
GluN1 subunits, while having a relatively small effect on the displacement of the T647 residues of the 
GluN2B subunits (Fig. 5c,g). A further increase in the diagonal distance at the level of the DEDE ring 
Figure 4. The rate of neurosteroid departitioning from the plasma membrane is fast. (a) Scheme of 
possible events taking place with steroid in the solution. The processes corresponding to the equilibria are: 
1, monomer binding to the membrane; 2, aggregates binding to the membrane; 3, monomer-aggregates 
equilibrium; 4, membrane solubilization (steroid leaving the membrane carrying membrane components). 
k represents rate constants. Scheme adopted from33. (b) Currents induced by changes in the membrane 
holding potential from − 60 to + 30 mV for 3 ms at a frequency of 200 Hz were used to assess changes in 
the membrane capacitance induced by fast application of PA-S (150 μ M) (inset). The slow component of 
the exponential fit to the offset of PA-S-induced capacitance change is shown for HEK293 cell attached to 
the surface of the cover glass (red line). Dashed line indicates cell capacitance before steroid application. (c) 
Changes in the membrane capacitance following fast application of PA-S in a lifted HEK293 cell. Dashed line 
indicates cell capacitance before steroid application. (d) Response induced in a lifted HEK293 cell transfected 
by GluN1/GluN2B receptors by fast application of glutamate (1 mM) was inhibited by PA-S (150 μ M) with 
slow off kinetics after PA-S wash.
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(by ~10 Å) results in the bending of the M3 helices of both GluN1 and GluN2B, with only a small effect 
on the diagonal distance at the TTTT ring (Fig. 5d,g). Additional displacement at the level of the DEDE 
ring indicates that the narrowest portion of the extracellular vestibule of the GluN1(T648A)/GluN2B 
receptor that limits PA-A movement to the central channel cavity is at the site of the GluN1(T648A) 
and GluN2B(T647) ring (Fig. 5a,f). When the extracellular vestibule was sequentially opened by 17.8 Å 
to reach the diagonal distance 37 × 38 Å (Cα to Cα) at the level of DEDE ring, the opening at the level 
of GluN1(T648A) and GluN2B(T647) was wide enough to allow the PA-A molecule to move from the 
extracellular vestibule to the central pore cavity. Taking into account the flexibility (rotation) of the AA 
residues, the minimal cross-section of this region was assessed to be 5.2 (GluN1 A-A) × 4.0 (GluN2B 
T-T) Å when vdW radii were taken into account and 10.9 × 10.0 Å when Cα to Cα was measured (Fig. 5f,g; 
Omin). The model for the WT GluN1/GluN2B receptor for the same displacement at the DEDE ring, as 
Figure 5. NMDAR channel opening and neurosteroid binding. (a) The membrane domains of the closed 
conformation of the NMDAR channel viewed from the extracellular side (GluN1 in red; GluN2B in blue). 
(b) The pore-forming segment (M3) of the GluN1/GluN2B receptor channel in a closed conformation. 
Residues T648 (GluN1) and T647 (GluN2B) at the narrow portion of the ion channel pore are shown as 
stick models (yellow) and residues D658 (GluN1) and E657 (GluN2B) at the most extracellular site of the 
M3 helices (green). (c) The position and shape of the M3 segments at the initial stage of opening induced 
by a stepwise (see Methods) increase in the transverse distance at the DEDE ring by a total of 1.0 Å. (d) The 
position and shape of the M3 segments at the open state induced by a stepwise increase in the transverse 
distance at the DEDE ring by a total 17.8 Å. (e) A slab of the molecular surface representation of the WT 
receptor at the region of the TTTT ring (as shown in d). (f) The representation of the open state of the 
GluN1(T648A)/GluN2B receptor induced by the same increase in the transverse distance as in the WT 
receptor (17.2 Å). (g) Comparison of the diagonal distances of the Cα atoms of T648 to T648 (GluN1) and 
T647 to T647 (GluN2B) of the WT receptor and A648 to A648 (GluN1) and T647 to T647 (GluN2B) of the 
mutated GluN1/GluN2B receptor induced by a stepwise increase in the diagonal distance between Cα atoms 
at the DEDE ring. The diameter of the channel pore represented by the channel vdW surface at the site of 
TTTT ring of the WT GluN1/GluN2B receptor (filled line) and GluN1(T648A)/GluN2B receptor (dashed 
line) calculated for the increase in the diagonal distance at D658 and E657 by 17.8 Å (Omin; filled symbols) 
and 19.0 Å (Omax; empty symbols). (h) Docking study of PA-S to the funnel formed by the M3 helices in the 
open channel configuration of the NMDAR. The most stable orientation is shown here.
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identified for the GluN1(T648A)/GluN2B receptor (17.8 Å), predicts the narrowest extracellular vesti-
bule dimension to be 4.5 × 3.6 Å when vdW radii are taken into account and 11.1 × 9.7 Å when Cα to 
Cα is measured (Fig. 5d,e,g; Omin). This is the smallest theoretical opening, since the displacement was 
selected in a way that allowed the forces between the steroid and the protein structure of the channel 
to be non-repulsive. The asymmetric position of the GluN1(T648) and GluN2B(T647) in the open con-
formation of the NMDAR ion channel explains the different contribution of GluN1 and GluN2B to the 
receptor inhibition by PA-S.
Estimates of the narrowest dimension of the extracellular vestibule of the WT NMDAR based on a 
model of the mutated receptor is biased because it is quite likely that the opening of the mutated recep-
tor is actually wider than would just suffice to allow PA-A to move across the vestibule. An alternative 
approach to estimating the dimension of the vestibule was based on an assumption that the open state 
of the WT GluN1/GluN2B receptor is just sufficient to allow the molecule of PA-A to move across the 
vestibule. Using the same approach as above, a stepwise increase in the diagonal distance at the level of 
the DEDE ring of the WT receptor by 19 Å (to reach the diagonal distance 38 × 39 Å (Cα to Cα)) induced 
an opening at the level of the TTTT ring sufficient to allow the steroid molecule to move from the 
extracellular vestibule to the pore central cavity. The upper limit of the narrowest extracellular vestibule 
dimension was estimated to be 5.5 × 5.0 Å when vdW radii were taken into account and 11.5 × 10.2 Å 
when Cα to Cα was measured (Fig. 5g; Omax).
Our proposed model of the WT NMDAR channel is compatible with previous estimates of the min-
imum cross-section of the channel permeation pathway in the conducting states 6.0 Å34, 5.5 Å35, and 
~4.5 × 5.7 Å36 and within the limits proposed for the channel diameter at the level of the activated extra-
cellular vestibule, which was estimated to be 7.3 Å35 and 11 Å16. Recently, molecular dynamic (MD) 
simulations were used to simulate the open conformation of the NMDAR channel37. In agreement with 
our model, the results of the MD simulations suggest a wide open extracellular vestibule of the pore; 
however, the dimensions of the narrowest region of the MD model (2 × 2 Å obtained by HOLE program–
which should be equivalent to vdW and comparable to about 8 × 8 Å between Cα atoms) indicate that 
the NMDAR channel has not reached the open state yet.
Spontaneous activity was described earlier for mutations within or in close proximity to the 
SYTANLAAF motif 25–28,31. In agreement with the experimental data, our model of the NMDAR indicates 
that the TTTT region is an important site for stabilizing the closed conformation of the ion channel. 
At the initial stages of channel opening, the original square geometry of the region changes first to a 
more compact diamond shape with a smaller pore diameter as the upper parts of the inner helices bend 
(Fig. 5c,d,g). The compact geometry allows an optimal distance to form vdW contacts as well as hydro-
gen bonds among the side-chain atoms of threonine residues, and as the distance between the helices 
grows further, nonsymmetric opening/gating at these threonine residues progresses. These data agree 
well with the results of experiments in which the cysteine accessibility method and helix cross-linking 
were used to show the asymmetric contribution of the M3 segments from the GluN1 and GluN2 subu-
nits to the opening of the extracellular NMDAR channel vestibule26,38. In contrast to the WT results, in 
mutants, the non-symmetric behavior and the reduction of pore diameter in the gating region during the 
initial steps of opening are less prominent (Fig. 5g). The asymmetric model of channel opening provides 
the structural basis for the experimentally observed functional and pharmacological differences between 
the GluN1 and GluN2B subunits the spontaneous activity differed 3.7-fold between GluN1(T648A)/
GluN2B and GluN1/GluN2B(T647A) receptors, and the value of the PA-S IC50 differed 5.4-fold.
Pregnanolone metabolites (allopregnanolone, pregnanolone, epipregnanolone, etiocholanone) sul-
fated in the C3-position are found in plasma in the nM range with small gender differences39,40. These 
compounds are also synthetized in the nervous tissue41,42 and are thought to act locally to modulate 
neuronal activity5. Sulfated pregnanolone metabolites were shown to have inhibitory action on GABA 
receptors and ionotropic glutamate receptors8,43. The relatively low potency of these compounds at the 
NMDAR may be misleading, since its aggregate concentration (representing the majority of the steroid 
in the water solution at biologically relevant concentrations) is likely to be much higher than that of its 
monomeric form (relevant for drug-receptor interaction). The calculations based on experimental data 
indicate that at the PA-S concentration corresponding to its IC50 at NMDARs, 99.5% of molecules present 
in the ECS will be in aggregates. However, at the membrane surface, the monomeric form is expected to 
be increased to the μ M range (see Supplementary Fig. 6). The results of the docking of PA-S to the site 
within the funnel formed by pore-forming helices indicate that this is indeed the case (Fig. 5h).
The docking did not suggest a single ligand binding site within the funnel, indicating that the appro-
priate size of the steroid molecule with respect to the channel vestibule is more critical than interactions 
of the steroid molecule with specific amino acids at this site. This agrees well with structural experiments 
indicating that the charge of the pregnanolone derivatives, as well as the substitution of the sulfate at C3 
and H at C5, C7, C11, C17 by different residues, had only a small effect on the steroid potency to inhibit 
NMDAR responses12,44–46.
The results of our electrophysiological experiments are compatible with steroid binding in the ion 
channel pathway at the receptor extracellular vestibule (SYTANLAAF motif). This is a highly conserved 
region among ionotropic glutamate receptors, and in the antagonist-bound state it occludes the ion 
channel permeation pathway21,27,47. In AMPA receptors, a mutation in this region (Lurcher mouse) 
induces neurological symptoms characterized on the molecular level by spontaneously opening ion 
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channels24,48. Similarly, this region is a critical determinant of channel gating in NMDARs27. Even though 
the site of action of neurosteroids (the extracellular vestibule) is distinct from that described for some 
voltage-dependent blockers such as Mg2+ 49,50, their mechanism of action is similar to that of blockers; 
i.e., the site is accessible upon receptor activation (use-dependent effect) and the agonist cannot disso-
ciate with the steroid bound51.
Synthetic homologues of naturally occurring pregnanolone sulfate inhibit NMDAR responses, cross 
the blood brain barrier, protect neurons against acute NMDA-induced cell death, improve behavioral 
performance in cognitive tasks, and, in addition, exhibit sedative, anticonvulsant, and analgesic prop-
erties9,44. In contrast to voltage-dependent inhibitors, neurosteroids do not induce psychomimetic-like 
behavior when administered to control experimental animals and, surprisingly, they ameliorate psy-
chomimetic behavior induced by systemic MK-801 administration11. This study shows that: a) inhibi-
tory neurosteroids bind at the extracellular channel vestibule of the NMDAR, b) allosteric inhibition is 
dependent on the receptor activation, and c) the inhibition involves stabilization of the NMDAR channel 
structure in an open blocked conformation. The mechanism of action presented here provides a molec-
ular blueprint for improving the design of therapeutic compounds targeting the NMDAR.
Materials and methods
Transfection and maintenance of cells. Human embryonic kidney (HEK293) cells were trans-
fected with expression vectors containing: GluN1–1a (GenBank accession number U08261)52; GluN2B 
(GenBank accession number M91562); GluN1-4a(F484A), (generous gift from Dr. J. J. Woodward)53 
(Smothers & Woodward, 2009); GluN3A (generous gift from Dr. S. A. Lipton)54 (GenBank accession 
number NM_138546); GluN1ΔN with deleted 354 amino acids in the NTD (32 to 386); GluN1ΔC with 
an introduced stop codon in 838 of the CTD GluN2BΔN) with deleted 354 amino acids in the NTD 
(32 to 386); GluN2BΔC with an introduced stop codon in 844 of the CTD55; GluR0 (GenBank accession 
number Synechocystis PCC 6803) (generous gift from Dr. M. L. Mayer)18; and green fluorescent protein 
(GFP) (pQBI 25, Takara, Tokyo, Japan) genes, as described previously12. The Quick-Change site-directed 
mutagenesis kit (Agilent Technologies, Santa Clara, CA, USA) was used to generate specific point muta-
tions in the M1/M3 region according to the manufacturer’s instructions using manually designed primers 
purchased from Sigma. Modified DNA plasmids were transformed into competent XL10-Gold E.coli 
cells, positive clones were selected, and isolated DNA was sequenced. Transfected cells were revealed 
by GFP epifluorescence. All mutations were verified by DNA sequencing (Macrogen, Seoul, Korea or 
SeQme, Dobris, Czech Republic). The amino acids are numbered according to the full-length protein, 
including the signal peptide, with the initiating methionine as 1.
Electrophysiological recording. Experiments were performed 24–48 hrs after transfection on cells 
transfected with GluN1/GluN2B/GFP plasmids. Whole-cell voltage-clamp recordings from HEK293 cells 
were made with a patch-clamp amplifier (Axopatch 200B; Axon Instruments, Inc., Foster City, CA) after 
a capacitance and series resistance (< 10 MΩ ) compensation of 80–90%.
Patch pipettes (3–5 MΩ ) were filled with a solution containing (in mM): 120 gluconic acid, 15 CsCl, 
10 BAPTA, 10 HEPES, 3 MgCl2, 1 CaCl2, and 2 ATP-Mg salt (pH-adjusted to 7.2 with CsOH). When 
GluR0 receptor responses were studied, intracellular solution contained (in mM): 120 gluconic acid, 
15 KCl, 10 BAPTA, 10 HEPES, 3 MgCl2, 1 CaCl2, and 2 ATP-Mg salt (pH-adjusted to 7.2 with KOH). 
Extracellular solution (ECS) contained the following (in mM): 160 NaCl, 2.5 KCl, 10 HEPES, 10 glucose, 
0.2 EDTA, and 0.7 CaCl2 (pH-adjusted to 7.3 with NaOH). Glycine (10 μ M), an NMDAR co-agonist, was 
present in the control and test solutions. All (PA-S and PA-A) solutions were made from freshly prepared 
20 mM PA-S and 5 mM PA-A stock in dimethyl sulfoxide (DMSO). The final dilution to ECS was made at 
50 °C and followed by 1 min sonication (SONOREX DIGITEC DT 100/H, BADELIN electronic, Berlin, 
Germany). The same concentration of DMSO was added to all extracellular solutions. Drug applica-
tions were made with a microprocessor-controlled multibarrel fast-perfusion system. Changes in the 
glutamate-induced current in HEK293 cells transfected by GluN1/GluN2B subunits were used to esti-
mate the rate of solution exchange around the cell. Standard ECS was switched to the ECS diluted by 
water (50%) during glutamate application. The osmolarity was adjusted by sucrose to match the stand-
ard ECS. Glutamate (1 mM), glycine (10 μ M) and pH was maintained constant in both solutions. The 
solution exchange rate was estimated to be τ = 4.3 ± 0.3 ms (n = 6) for lifted cells and τ = 12.0 ± 0.9 ms 
(n = 6) for the attached cells.
Experiments were performed at room temperature (21–25 °C). Data were collected (low-pass filtered 
at 2 kHz and sampled at 10 kHz) and analyzed using pClamp 10 (Molecular Devices). Unless otherwise 
mentioned, error bars represent SEM; statistical comparison of groups was performed using Student’s 
t-test (p < 0.05 was used to determine the significance).
The IC50 was determined from a single dose of a steroid using the formula
× ( − /= ) ( )IC [steroid] I I1 150
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where I is the relative degree of inhibition and [steroid] is the steroid concentration used. Calculations 
of IC50 were made assuming 100% inhibition at saturating steroid concentration this is valid for both 
PA-S and PA-A12,13.
The I–V relation of the PA-A inhibitory effect was fitted to the Boltzmann function equation of the 
form:
( ) = ( − )/( + − ) ( )
−I V a g V V a A e[PA ] 2bV0 rev
in which g0 is the estimated conductance of the NMDAR whole-cell response in the absence of extra-
cellular PA-A, Vrev is the reversal potential of NMDA-induced current and a, b are parameters with the 
following interpretation:
= ( )a K e 3bVd
where Kd represents the apparent dissociation constant for PA-A binding to the NMDAR at a given 
membrane potential (V) and:
= δ /( ) ( )b F RT2 4
where δ indicates the apparent electrical distance of the PA-A binding site from the outside of the mem-
brane and F, R and T have their standard thermodynamic meanings56. Unless otherwise noted, record-
ings were performed at a holding potential of − 60 mV (values of the holding potential were corrected 
for the liquid junction potential, 14 mV).
Membrane capacitance was estimated by examining the integrated capacitive current (sampled at 
30 kHz at 10 kHz filter cutoff frequency) evoked by depolarizing or hyperpolarizing voltage pulses from 
− 60  mV to +30 mV for 3 ms delivered at 200 Hz.
All drugs, unless otherwise stated, were purchased from Sigma-Aldrich (St. Louis, MO, USA). PA-S 
and PA-A were synthesized as described previously12,57. The structures of all synthesized steroids were 
confirmed by IR, NMR, MS and HR-MS spectra.
Light scattering analysis. Light scattering (Zetasizer Nano ZS, Malvern Instruments, United 
Kingdom) was used to characterize particle size of PA-S in ECS. PA-S was dissolved in DMSO at a con-
centration of 20 mM and then in the ECS at a final concentration of 5 nM to 150 μ M PA-S. This solution 
was sonicated (Ultrasonic Sonorex Super RK 103 H, Bandelin electronic GmbH & Co. KG, Germany) 
for 1 min. Light scattering analysis was repeated six times for each sample at 25 °C.
Analysis of the steroid concentration in the cytoplasmic membrane. All animal manipulations 
were conducted in accordance with the Animal Protection Code of the Czech Republic and correspond-
ing directives of the European Community Council (2010/63/EC). Experiments were approved by the 
Animal Care and Use Committee of the Institute of Physiology of the Academy of Sciences of the Czech 
Republic. Blood was collected from one adult Wistar rat, heparinized, and spun down at 1,000 g for 
10 min. Cells were washed once with PBS, briefly spun down and the pellet resuspended in a minimum 
amount of ECS. Cells were counted and 200 μ l aliquots (~3*109 cells) were taken for the experiment. 
Cell membranes were prepared by 30 min erythrocyte lysis in distilled water followed by centrifugation 
at 25,000 g for 10 min and resuspension in 200 μ l of ECS. Cell membranes were incubated for 2 min 
with PA-S solution in ECS at the final volume of 500 μ l, followed by a spin down at 20,000 g for 2 min. 
Supernatants were taken for liquid chromatography-mass spectrometry analysis (HPLC-MS). Solution 
of PA-S without membranes served as a control. HPLC-MS analysis was performed on a system con-
sisting of Accela 1250 pump, Open Accela autosampler and Orbitrap Velos mass spectrometer (Thermo 
Scientific, USA). The analytes were separated on the Kinetex C18 column 100 mm × 2.1 mm × 1.7  μ m 
and the mobile phase (solvent A: aqueous solution of acetic acid (0.1%); solvent B: methanol) eluted in 
isocratic solution (ratio 90:10) at a flow rate of 150 μ l/min. The column temperature was maintained at 
25 °C. The injection volume was 10 μ l. The mass spectrometer equipped with an electrospray ion source 
was used for the detection of analytes in the selective reaction monitoring (SRM) mode in negative 
ionization. The parameters of the mass spectrometer were optimized as follows: spray voltage − 2500 V 
(negative ionization mode), temperature of ion transfer tube 350 °C, temperature of H-ESI vaporizer 
350 °C, pressure of sheath gas (nitrogen) 40 psi, flow of auxiliary gas (nitrogen) 15 arbitrary units. The 
data were acquired and processed using the software Xcalibur 2.1.0 (Thermo Scientific, USA).
Molecular modeling of steroids. 3-D structures of steroids were determined using Hyperchem 8 
(Hypercube, Gainesville, FL, USA). The molecular geometry and partial charges were optimized by a 
semiempirical method PM3 considering the appropriate total charge of a molecule and singlet state. 
Subsequently, a general protocol for obtaining the lowest energy conformers by simulated annealing 
was used: optimized starting structure was subjected to a dynamic run (0.2 ps heating from 300 to 
1000 K), 1 ps equilibration, and 2 ps cooling to 200 K, followed by energy minimization. Every subse-
quent run started from the previously minimized structure. A set of 100 structures was obtained for each 
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compound, from which the lowest energy conformation was taken. The Polak-Ribiere conjugate gradient 
method for energy minimizations was used for convergence (less than 0.04 kJ. M−1 RMS force). Force 
field MM+ was used for all computations. All calculations were done in vacuo.
Homology modeling. For the homology model of the NMDAR the crystal structure of AMPA and 
NMDARs were used21,58,59. The missing residues were added using the MODELLER 9v6 suite of pro-
grams60, resulting in a full length 3D structure of the receptor. The AMPA domain (GluA2) amino 
acid sequence was aligned with the GluN1 and GluN2B sequences using clustalw261 program, and this 
alignment and the NMDA crystal structure were used to prepare the full length NMDAR models (3310 
residues in total).
Modeling of ion channel open state. Molecular modeling features of MODELLER package, includ-
ing the conjugate gradient optimization and molecular dynamics, were used for a study of pore opening. 
Opening of the channel was modeled by elongating the distance between pairs of GluN1 and GluN2B 
domains separately (anchored by the Cα atoms of the topmost residues within the pore-forming heli-
ces) as well as the concerted opening involving both pairs. A stepwise optimization of the structure was 
employed; the exact protocol consisted of a series of conjugate gradient optimizations, short MD, fol-
lowed by a conjugate gradient optimization for each increment of the above mentioned distance. The dis-
tance was varied within − 5 Å to 20 Å from the original closed conformation of the NMDAR homology 
model. We decided to include secondary structure restraints for the innermost helices forming the pore. 
Restraining the entire inner helices presents an “extreme case” that makes the central helices more rigid 
in full length by restraining their alpha helical secondary structure. The most effective attempt restrained 
only the top part of the helices: the secondary structure was restrained for the topmost 8 residues of both 
GluN1 and GluN2B pore-forming helices and the distance changed in 0.2 Å increments. These simple 
restraints (only one/two interatomic distances and the secondary structure) were used in order to intro-
duce as small a perturbation to the mechanism of channel opening as possible. The relative direction of 
the movement of pore-forming helices or the interdomain orientation was thus not restrained.
Ligand docking. The docking of the PA-S and PA-A steroids to a series (intermediates of the open-
ing models) of NMDAR homology structures was performed using the autodock suite of programs. 
The ligand atomic charges were obtained systematically by a standard quantum chemical procedure by 
HF/6-31G* electrostatic potential fit at the B3LYP/6-31G* gradient optimized geometry. Steroids were 
docked into the homology model of GluN1/GluN2B receptor using Python Molecular Viewer (PMV 
1.5.6 rc3)62. Each steroid was allowed to sample docking poses in a box (70 × 70 × 90 grid points with 
0.375 Å spacing) centered at the level of the gating residues. The residues at the surface of the forming 
channel were considered flexible. Four genetic algorithm docking runs of 50 were performed and data 
combined to find the most probable ligand “binding site”. In order to accurately identify the minimum 
necessary displacement corresponding to an open state, a local search was performed with ligand posi-
tioned between the gating residues.
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